A national data supplier provided palivizumab claims for Medicaid and commercial health plans across the nation from January 2019 through December 2019.
- Health plans deny 40% of palivizumab prescriptions for premature infants born between 29 and 36 weeks gestation.
- One in every four prescriptions is denied for infants who should qualify for coverage under standard insurance policies.
